X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TTP399 (cadisegliatin) is an investigational liver-selective glucokinase activator that has been studied in healthy volunteers and in patients with type 1 and type 2 diabetes.
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
vTv will utilize the net proceeds to finance the initial Phase 3 trial of its primary product candidate, TTP399 (cadisegliatin), a glucokinase activator intended for treating type 1 diabetes.
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Samsara BioCapital, LLC
Deal Size: $51.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 28, 2024
Details:
The proceeds will provide vTv with important financial support for preparing the launch of the TTP399 (cadisegliatin), a potential adjunctive therapy to insulin, phase 3 program in the treatment of type 1 diabetes.
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Reneo Pharmaceuticals
Deal Size: $4.4 million Upfront Cash: Undisclosed
Deal Type: Agreement November 01, 2023
Details:
TTP488 (azeliragon) is an orally administered small molecule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the glioblastoma microenvironment.
Lead Product(s): Azeliragon
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
In addition to the investment, the agreements set forth the terms under which vTv will leverage the CinRx team’s industry experience to collaborate on the oversight of the clinical trials for pharmaceutical products that contain TTP399.
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: CinPax
Deal Size: $10.0 million Upfront Cash: $6.0 million
Deal Type: Agreement July 25, 2022
Details:
Results confirmed TTP399 improves glycemia without increasing hypoglycemia and suggest a protective effect of TTP399 against DKA in individuals with T1D.
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Details:
The agreements set forth the terms under which vTv and an affiliate of G42 plan to collaborate on clinical trials for pharmaceutical products that contain TTP399, including G42’s affiliate funding a portion of the Phase 3 clinical trials for TTP399.
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: G42 Investments
Deal Size: $55.0 million Upfront Cash: $12.5 million
Deal Type: Collaboration June 01, 2022
Details:
TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population, has been tested in almost 600 patients to date with no evidence of diabetic ketoacidosis.
Lead Product(s): TTP399
Therapeutic Area: Endocrinology Product Name: TTP399
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2022
Details:
HPP737 is a novel, potent, orally administered PDE4 inhibitor discovered by vTv Therapeutics. HPP737 has been well tolerated across the range of doses tested, with few or no gastrointestinal adverse events, such as nausea, vomiting or diarrhea.
Lead Product(s): HPP737
Therapeutic Area: Dermatology Product Name: HPP737
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2021
Details:
HPP737 is a novel, potent, orally administered PDE4 inhibitor discovered by vTv Therapeutics. PDE4 is a validated therapeutic target for the treatment of a variety of disorders including psoriasis.
Lead Product(s): HPP737
Therapeutic Area: Dermatology Product Name: HPP737
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
